Syneron Tech
- Biotech or pharma, therapeutic R&D
Syneron Bio is a cutting-edge macrocyclic peptide therapeutics company, propelled by next-generation AI capabilities.
Established in mid-2022, the company has pioneered a range of first-in-class cyclic peptides aimed at tackling intracellular undruggable targets for cancer and developing oral peptides for autoimmune and cadiovascular diseases and peptide drug conjugates for oncological disease with two expected to file for IND in 2025.
Since its inception, Syneron has secured four rounds of financing, drawing top-tier investors such as AstraZeneca, AZ-CICC, Lilly Asia Venture, Pfizer, Hillhouse, 5Y Capital, Lenovo Capital, Gree Capital and Sinovation Capital.
The company has also established platform and asset collaborations with MNCs such as Astra Zeneca and Roche.
Address
BeijingChina
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}